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Abstract
Background: 10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to
cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab
(P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed
in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or
the combination of T + P), in combination with perioperative CT for localized HER2+ GC.
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Methods: This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC
TNM7 tumor stage Ib-III) will be centrally determined. Two hundred and-fifteen patients from 52 sites in 14 countries will
be centrally randomized (1:2:2 ratio) to one of the following treatment arms:
1. Standard: CT alone. CT regimens will be FLOT (5-FU, leucovorin, oxaliplatin, taxotere) CapOx (capecitabine,
oxaliplatin) or FOLFOX (5-FU, leucovorin, oxaliplatin) according to investigator’s choice in Europe, and
cisplatin/capecitabine in Asia.
2. Experimental arm 1: CT as in control group, plus T (8mg/kg loading dose, followed by 6mg/kg every 3 weeks) at
day 1, independent of CT chosen for 3 cycles of 3 weeks before and after surgery.
3. Experimental arm 2: CT plus T as in experimental arm 1, plus P (840mg every 3 weeks) on day 1.
Adjuvant treatment with T or T + P will continue for 17 cycles in total. Stratification factors are: histology (intestinal/non-
intestinal); region (Asia vs Europe); location (GEJ vs non-GEJ); HER2 immunohistochemistry score (IHC 3+ vs IHC 2+/FISH+)
and chemotherapy regimen. Primary objective is to detect an increase in the major pathological response rate from 25 to
45% either with CT plus T alone, or with CT plus the combination of T and P.
Discussion: Depending on the results of the INNOVATION trial, the addition of HER2 targeted treatment with either T or
T and P to CT may inform future study designs or become a standard in the perioperative management HER2+ GC.
Trial registration: This article reports a health care intervention on human participants and was registered on July 10,
2014 under ClinicalTrials.gov identifier: NCT02205047; EudraCT: 2014–000722-38.
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Background
Gastric cancer (GC) is the 5th most common malignancy,
and third leading cause of cancer-related mortality world-
wide [1]. Since the publication of the “MAGIC” trial [2],
D2 resection in a high-volume surgical center and peri-
operative chemotherapy with epirubicin, cisplatin and
5-FU (ECF) became standard of care in Europe [3] for
medically fit patients with resectable, T1N +M0 to T4N +
M0 gastric cancer. In contrast, in Asia adjuvant chemo-
therapy with S-1 [4], or capecitabine and oxaliplatin [5]
are standard of care for potentially curative resectable GC.
The results of the “MAGIC” trial have recently been
challenged by the presentation of the results from the
AIO-FLOT-4-trial [6]. This randomized phase III study
compared the perioperative chemotherapy regimens
FLOT (5-FU, leucovorin, oxaliplatin and docetaxel) with
ECF (epirubicine, cisplatin and 5-FU), and demonstrated a
significant improvement in overall survival (median
survival: 35 vs.50 months; projected 5-year-survival: 36
versus 45%) for patients treated with FLOT. Nevertheless,
more than 40% of patients treated with perioperative
FLOT have either a minimal or no pathological response
to this treatment (TRG 3) (according to Becker et al. [7]
or cannot proceed to surgery, and further improvement of
therapy for GC patients is urgently required.
Between 10 and 20% of patients with GC are HER2
positive (HER2+) [8, 9]. In patients with advanced, HER2+
GC or gastro-esophageal junction (GEJ) adenocarcinoma,
the addition of trastuzumab (T) to standard cisplatin/
fluoropyrimidine chemotherapy improved overall survival
significantly [10]. In HER2+ breast cancer, the addition of
T to standard neoadjuvant chemotherapy significantly
improved both, pathological complete response rates and
event-free survival (defined as: time from randomization
to disease recurrence or progression): 71% versus 56% at
3 years; Hazard Ratio (HR) = 0.59, p = 0.013) [11]. A
further significant improvement of pathological complete
response rates after neoadjuvant treatment of HER2 posi-
tive breast cancer has been observed recently, when the
dimerization inhibitor pertuzumab was added to trastuzu-
mab and chemotherapy (pathological complete response
rates 29% versus 45%) [12]. In advanced, HER2+ breast
cancer, the addition of pertuzumab to trastuzumab and
docetaxel increased progression-free survival from 12.4 to
18.5months (HR 0.62; 95% CI 0.51–0.75; p < 0.001) [13],
and overall survival from 40.8 (95% CI 35.8–48.3) to 56.5
(95% CI 49.3 – not reached) months [14]. In contrast, in
advanced HER2+ GC, the addition of pertuzumab to
capecitabine/cisplatin/trastuzumab improved survival by
3.3 months, which did not reach statistical significance
(p = 0.585) [15]. With respect to targeted, perioperative
treatment of HER2+ GC and GEJ cancers, data from
randomized clinical trials are lacking.
Methods
Study design and aim
EORTC 1203 -“INNOVATION” (https://www.eortc.org/re-
search_field/clinical-detail/1203/) is a prospective, multicenter,
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international, randomized phase II trial which aims to
evaluate the effect of targeted treatment using either
trastuzumab, or the combination of trastuzumab plus
pertuzumab in combination with perioperative chemo-
therapy on the pathologic response rate in patients with
localized (stage IB-III according to TNM, 7TH edition)
GC or GEJ adenocarcinoma. The trial was designed by
the EORTC, which is the legal sponsor. It is conducted
by EORTC as leading group, in cooperation with the
Korean Cancer Study Group (KCSG) and the Dutch
Upper Gastrointestinal Cancer Group (DUCG). Surgical
quality assessment is performed in collaboration with the
Japanese Clinical Oncology Group (JCOG).
Study flow
After signing the informed consent and registration of
potentially eligible patients, formalin fixed paraffin
embedded material from the diagnostic biopsy is sent to
a central laboratory for determination of the HER2
status. Only patients with a centrally determined, positive
HER2 status, who fulfill the eligibility criteria mentioned
below, are randomized centrally by the EORTC
randomization system in the following three treat-
ment arms (Fig. 1):
Interventions: In the initial version of the protocol
(version1.0 of August 29, 2014), based on the evidence
available at that time, cisplatin and 5-FU/capecitabine
[16] were selected as chemotherapy backbone. After
publication of the results of the FLOT-4 trial [17], the
protocol was amended (version 4.1 of 11/12/2017) to
allow - in Europe – either FLOT, FOLFOX or CapOx as
chemotherapy backbone, according to what the investi-
gator considers as in the best interest of the patient. By
contrast, in absence of data for FLOT in Asian patients,
and after discussion with the Asian investigators, the
chemotherapy backbone of cisplatin and 5-FU/capecita-
bine in Asian patients remains unchanged. A detailed list
of all protocol changes is provided in Appendix 2.
Standard arm - chemotherapy alone
– Before amendment 4.1 (and continued in Asia after
this amendment): Cisplatin (80 mg/m2 every 3
weeks) and capecitabine (1000 mg/m2 twice daily
every 2 out of 3 weeks), or 5-FU (800 mg/m2/day for
5 days every 3 weeks) for 3 cycles before and after
surgery.
– After amendment 4.1 in Europe: FLOT is
administered in cycles of 2 weeks for 4 cycles
(= 8 weeks) on day 1, 15, 29 and 43 pre- and
postoperatively, with Docetaxel 50mg/m2, followed
by Oxaliplatin 85mg/m2 diluted with 250 to 500ml of
Fig. 1 INNOVATION Study (Version 4.1) flow chart. CapOx: Capecitabine, Oxaliplatin; mFOLFOX 6: Modified FOLFOX 6; FLOT: 5-fluorouracil (FU),
Leucovorin, Oxaliplatin and Taxotere; CisPT: Cisplatin; Cape: Capecitabine; Her-2: Human epidermal growth factor receptor type 2; GE-junction:
Gastroesophageal junction; w: weeks
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5% glucose solution as a 2 h infusion, leucovorin 200
mg/m2 over 2 h and 5-FU 2600mg/m2 as a 24 h-infu-
sion. Alternatively, either CapOx is given for 3 cycles
of 3 weeks (=9 weeks) on day 1, 22 and 43 pre- and
postoperatively, with Oxaliplatin 130mg/m2 on day 1,
and followed by capecitabine given orally at a dose of
1000mg/m2 twice daily from the evening of day 1 to
the morning of day 15 every 3 weeks or mFOLFOX6
is given for 4 cycles of 2 weeks (=8 weeks) on day 1,
15, 29 and 43 pre- and postoperatively, with
oxaliplatin at a dose of 85 mg/m2, followed by
leucovorin 400mg/m2 iv over 2 h on day 1, and 5-FU
400mg/m2 iv bolus on day 1, then 1200mg/m2/d × 2
days over 46–48 h continuous infusion every 2 weeks.
Chemotherapy should be restarted 4 to 6 weeks after
surgery, if the patient has sufficiently recovered, in all
trial arms
Experimental arm 1
Chemotherapy as in standard arm, plus trastuzumab
(8mg/kg loading dose, followed by 6mg/kg every 3 weeks)
on day 1, 22 and 43, independent of the chemotherapy
regimen chosen, for 3 cycles of 3 weeks before and
after surgery.
Experimental arm 2
Chemotherapy plus trastuzumab as in experimental
arm 1, plus pertuzumab (840 mg every 3 weeks) at
day 1, 22 and 43, independent of the chemotherapy
regimen chosen.
Surgery is scheduled within 2–4 weeks after the
completion of cycle 3 in a 3-week-cycle, and after
completion of cycle 4 in a 2-week-cycle if the white
blood count has normalized again and the patient is
clinically deemed fit to undergo major surgery. Sur-
gery is performed according to the Japanese Gastric
Cancer Treatment Guidelines 2014 (version 3) [18].
The extent of the surgical resection depends primarily
on the location of the tumor and is either an ex-
tended total, partial or subtotal gastrectomy, or – for
tumors of the GEJ – esophagogastrectomy and re-
construction via gastric tube or extended total gas-
trectomy according to the decision of the surgeon.
Surgical CRFs, mandatory intra-operative photo docu-
mentation, the operative report, the pathology report,
central pathology review and assessment of surgical
complications according to Dindo [19] will be used
for surgical quality assessment.
Maintenance treatment is performed with trastuzu-
mab alone or trastuzumab plus pertuzumab in experi-
mental arms 1 and 2 starting after the end of adjuvant
chemotherapy, and continuing for a total of 17 cycles
from the start of neoadjuvant treatment.
Main inclusion criteria for REGISTRATION
Histologically proven, gastric or GEJ adenocarcinoma
(Siewert I-III), absence of distant metastases on CT
scan of thorax and abdomen, age > 18 years, WHO
performance status 0–1 in a patient judged medically
fit for gastrectomy/esophagogastrectomy as decided
by the investigator.
Main inclusion criteria for RANDOMIZATION
HER2 overexpression, as determined by central testing
using immunohistochemistry (IHC 3+) or the combin-
ation of IHC 2+ and HER2 FISH (Fluorescence In
Situ-hybridization) positive. Amenable to gastrectomy/
esophagogastrectomy with curative intent as confirmed
by a multidisciplinary team discussion. UICC (7th
edition) tumor stage Ib to III, as defined by CT scan
and/or MRI. Endosonography (EUS) is recommended,
but not mandatory. Absence of contraindications for any
of the study treatments. No prior chemotherpy or
antibody treatment. Adequate organ function. Written
informed consent according to ICH/GCP, and national/
local regulations.
Primary endpoint: major pathological response rate
(< 10% vital residual tumor cells) according to Becker et
al. [20].
Secondary endpoints: are R0 resection rate, patho-
logical complete response rate, locoregional failure,
distant failure, progression-free survival according to
RECIST v1.1, recurrence-free-survival from surgery,
overall survival and adverse events (according to
CTCAE v 4.0).
Schedule of investigations
Before registration: histologic diagnosis of gastric or
GE-junction adenocarcinoma, written informed consent
for screening.
During screening: Central HER2 assessment, CT scan
of thorax and abdomen (needed within 35 days of treat-
ment start), hepatic MRI in case of suspected liver
lesions, brain MRI if clinically indicated echocardio-
graphy, ECG, laboratory tests including hematology and
biochemistry, assessment of adverse events, multidiscip-
linary team discussion of surgical resectability and
general operability. Echo-endoscopy and laparoscopy
are not mandatory and performed at the investigator’s
discretion.
After randomization/before each (neo) adjuvant
chemotherapy cycle: Clinical and laboratory tests,
including hematology and biochemistry, assessment of
adverse events.
Before surgery: Multidisciplinary team discussion of
surgical resectability and general operability, clinical and
laboratory tests, including hematology and biochemistry,
assessment of adverse events.
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During maintenance treatment: Clinical and labora-
tory tests, including cardiac evaluation by ECG and
echocardiography every three months.
During adjuvant/maintenance treatment and follow-
up: CT-scan of thorax and abdomen every 6months in
year 1 and 2, yearly thereafter.
Sample size calculation and analysis populations:
Based on the results in breast cancer, where the addition
of trastuzumab to neoadjuvant treatment with docetaxel
increased the total pathologic complete response in the
primary tumor and axillary nodes (tpCR) from 19 to
38% [11], and where the addition of pertuzumab to the
combination of trastuzumab and chemotherapy further
increased pathologic tpCR from 31 to 45% [12], the
primary objective of the “INNOVATION” trial is to
detect an increase in the major pathological response
rate of the primary tumor from 25 to 45% either with
chemotherapy plus trastuzumab alone, or with chemo-
therapy plus the combination of trastuzumab and per-
tuzumab. A comparative design with an increased
one-sided type I error of 10% will be applied to test each
experimental arm versus the control arm. To have 80%
power to detect an increase from 25 to 45% in major
pathological response rate between the control arm and
each experimental arm using a Z-test for the comparison
of two sample proportions with a one-sided type I error
of 10%, 38 patients are required in the control arm and
76 patients in each experimental arm. A stepwise testing
procedure will be used in order to avoid inflation of the
one-sided type I error due to multiple testing. Therefore,
the hypothesis of an increase in major pathological
response rate with both trastuzumab and pertuzumab
will first be tested using a one-sided type I error of 10%.
If significant, the hypothesis of an increase in major
pathological response rate with trastuzumab alone will be
tested. As such, the overall one-sided type I error will be
kept below 10%. Analysis populations are the following:
 Per protocol population: All patients who are
eligible and have started their allocated treatment
(at least one dose of the study drug(s) planned as
pre-operative treatment).
 Safety population: All patients who have started
their allocated treatment (at least one dose of the
study drug(s) planned as pre-operative treatment).
 Resected population: All eligible patients who have
started the allocated pre-operative treatment, were
operated and achieved a R0 or R1 resection.
The primary analysis of the major pathological response
rate will be performed in the per protocol population with
a non-missing assessment of pathological response. This
includes all patients in the per protocol population who
have had a resection and for whom the tumor regression
according to Becker et al. has been assessed by the central
pathology laboratory or who did not proceed to surgery or
did not have a resection for any reason and therefore will
be considered as not having a major pathological response
in the analysis. Thus, missing data for the primary end-
point will only occur if a patient has had a resection and
the central pathology review of the resection specimen is
not possible for technical reasons e.g. if the resection
specimen is not provided at all by the local pathologist or
are not provided in sufficient quality or quantity. These
patients will be excluded from the analysis. All reasonable
efforts will be made to minimize this risk, e.g. the local
pathologists will receive detailed information (written
pathologist guidelines, web-based training) about the
material and procedure necessary for central pathology
review and will be asked to sign that he agrees to provide
the material required according to protocol during the
evaluation of the feasibility of the study in a center.
Assessment of pathologic response will be performed
independently by two senior pathologists specialized in
gastrointestinal cancers, who will be blinded to treatment
allocation. Inter-observer variability will be adjucidated by
a third expert pathologist. In contrast, caregivers and
patients will not be blinded to the allocated treatment.
Randomization (both generation of the allocation se-
quence and assignment of participants to interventions)
will be performed centrally by the EORTC computerized
randomization system. Randomization between the three
arms will continue until the required number of patients
for the primary analysis is reached (38 patients in the
control arm and 76 patients in each experimental arm).
Using a safety margin of 10% in each arm, a maximum of
215 patients will have to be randomized in total. After ana-
lysis of the primary endpoint the advice of the EORTC In-
dependent Data Monitoring Committee (IDMC) (https://
www.eortc.org/governance/committees/) will be sought
regarding the possible conduct of a phase III trial. Follow
up will continue until death or for a minimum of 6 years
after end of treatment.
Ethical considerations
The study protocol has been approved by the competent
ethics committee as requested by the applicable national
legislation. It is conducted in agreement with either the
Declaration of Helsinki (available on the World Medical
Association web site [21] and/or the laws and regu-
lations of the country, whichever provides the greatest
protection of the patient as well as according to the ICH
Harmonized Tripartite Guideline on Good Clinical
Practice (ICH-GCP), available online at [22].
Written informed consent according to the above
mentioned regulations is obtained prior to any study-
related procedure by the investigator in each partici-
pating center.
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Discussion
The development of HER2 targeting treatments for
breast cancer is one of the greatest achievements in
modern oncology, and permitted to improve median
survival for patients with metastatic, HER2+ breast
cancer from about 12months to more than 50months
in a recently published trial [14].
Subsequently, HER2 targeting treatments were also
developed in gastric cancer. Trastuzumab was the first
targeted agent, which – when added to palliative chemo-
therapy – demonstrated a significant survival benefit in
patients with metastatic GC [10], without the side effects
of chemotherapy or other new safety signals. As such, it
was a milestone in drug development. Whereas pertu-
zumab significantly improved survival in patients with
metastatic breast cancer, this was not the case in
patients with metastatic GC as reported in the
JACOB-trial recently. Despite a survival benefit of 3.3
months, this was not statistically significant according
to the hypothesis specified in the protocol. However, the
question whether the integration of HER2 targeting drugs
in perioperative chemotherapy may further improve
treatment outcomes in patients with localized or locally
advanced resectable GC remains one of the major open
questions in the current management of GC patients.
While trastuzumab is certainly the most promising drug
to study in this indication, pertuzumab might still be able
to increase the benefit of trastuzumab when given at an
earlier time point in the evolution of this disease and for a
longer time. The “INNOVATION”-trial has the advantage
to assess the relative benefit of both trastuzumab and
pertuzumab individually in the perioperative treatment of
GC patients. In addition, as not all patients are eligible for
treatment with FLOT, and given the currently limited
experience of FLOT outside of Germany at present,
“INNOVATION” will allow a preliminary estimation of
the relative benefit of these antibodies with different
chemotherapy backbones (CF and FOLFOX or CapOx).
In addition to systemic treatment, it is well established
that the quality of surgery has a major impact on the
patients’ outcome. Surgical quality assurance is therefore
another key feature of this study protocol. An integrated
approach [23, 24] has been adapted for this study
through the central review by independent surgeons and
pathologists from JCOG and EORTC. Data from surgical
and pathology case report forms, pathology review,
intraoperative photographs and macroscopic pictures of
the resected specimen will be reviewed to assess com-
pleteness of surgical treatment. Thirty and 90 day
surgical complications, graded by the Clavien-Dindo
Classification [19], will also be reviewed.
Finally, assessment of histopathological tumor regres-
sion may be challenging as different tumor regression
systems are used by local pathologists. To minimize the
risk of bias, the primary endpoint, major pathological
response, will be assessed centrally, by two expert
gastrointestinal pathologists, according to a previously
published, validated protocol [20], with discrepancies
being resolved by a third expert gastrointestinal patho-
logist. As major pathological response rate remains a
surrogate endpoint, the final decision to proceed with
further development of trastuzumab and pertuzumab,
either alone or in combination, in this indication will
also consider other endpoints, such as safety, progres-
sion- free survival and overall survival.
Furthermore, there is evidence to suggest that the bio-
logy of gastric cancer biology differs significantly between
Asian and Caucasian patients [25], and a large variability
in the results of surgery [2, 4, 26] and several systemic
treatments [27, 28] between different geographical regions
has been observed since years. Thus, it is unclear if treat-
ment benefits observed in one region of the world will
have the same magnitude in other regions.
“INNOVATION” is a unique example of an academic,
international, multidisciplinary collaboration of four
leading academic groups in upper GI-cancer: EORTC,
DUCG and KCSG, with JCOG being responsible for
the surgical quality assurance, under the leadership of
EORTC. Due to its design and recruitment in different
European countries, as well as Korea and Singapore,
“INNOVATION” will permit to estimate the relative
benefit of perioperative HER2 targeted treatment with
trastuzumab and pertuzumab individually in different
geographical regions, and with different chemotherapy
backbones and provide a rational basis for the design
of future confirmatory studies in patients with re-
sectable GC.
Appendix 1
Item 2b: All items from the WHO Trial Registration
Data Set (if not described in the protocol text).
Primary registry and trial identifying number,
including date of registration and secondary identifying
numbers: see abstract.
Primary sponsor: European Organization for Research
and Treatment of Cancer (EORTC), Avenue E. Mounier-
laan 83/11, 1200 Bruxelles, Belgique. Email:eortc@eortc.
be, https://www.eortc.org.
Secondary sponsor: see declarations. The trial is
supported by an educational grant by F. Hoffmann La
Roche to EORTC.
Contact for public queries: 1203@eortc.be
Contact for scientific queries: 1203@eortc.be
Public title: EORTC-1203-GITCG: INNOVATION-
trial.
Scientific title: Integration of trastuzumab, with or with-
out pertuzumab, into perioperative chemotherapy of HER-2
posiTIve stomach cancer: the INNOVATION-TRIAL.
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Countries of recruitment (as of 19.09.2018): South
Korea, Germany, Estonia, United Kingdom, Italy, Spain,
France, Israel, Switzerland, Norway, Portugal, Belgium.
Health condition or problem studied: HER-2 posi-
tive, gastric and gastroesophageal junction cancer.
Interventions: see methods.
Key inclusion and exclusion criteria: see methods.
Study type: Interventional, Allocation: randomized.
Masking: single blind (outcomes assessor). Primary
purpose: treatment, phase II.
Date of first enrolment: 01.12.2015.
Target sample size: n=215
Recruitment status: 69 patients as of 19.09.2018.
Primary outcomes: see methods.
Key secondary outcomes: see methods
Appendix 2
Summary of protocol changes from protocol v3.0 to 4.0
- Change of chemotherapy backbone: in Europe, the
regimen will be selected between FLOT, CapOX por
mFOLFOX6; in Asia, cisplatin +capecitabine or
5-FU.
This scientific amendment was necessary after the pres-
entation of the results of the FLOT-4-trial at ASCO 2017,
which demonstrated a significantly better progression-free
and overall survival for perioperative treatment with
FLOT, as compared to ECF. Both, dose modification
and supportive care recommendations for treatment
with FLOT have been inspired by those used in the
FLOT-4 study, which were generously provided by the
author. Cisplatin is being kept as an option as it is still
standard of care in Korea, and efficacy benefit of other
regimen yet have to be demonstrated in these patients
(section 4 trial design, page 28; therapeutic drug regimen,
section 5; newly added Appendix L).
- A safety run has been introduced in the pro-
tocol, given the change of background chemotherapies
(section 4.1).
- A definition of ‘high dose corticosteroids’ was
inserted (section 3.2).
- Clarification was added, that DPD testing should be
done according to local guidelines (section 3.2; section
5.4.5.1.1).
- Dose reduction upon grade 2 or 3 nausea or vomi-
ting has been adapted (appendix L for Cisplatin-treated
patients).
- Recommendations regarding the procedures in case
of tubular damage and low Mg/Ca were added in Table 9
(Appendix L).
- Measures to be taken after assessment of ototoxicity
and sensory neural damage were clarified (Appendix L,
section ‘Other precautions’).
Furthermore:
- The numbers of treatment cycles and timelines for
follow-up have been clarified and made consistent be-
tween the protocol and PISIC.
- For enrolled patients, the side effects and toxicities
have been updated in the protocol and PISIC based on
the new versions of the IBs of Pertuzumab.
and Trastuzumab.
- A PISIC specific to the new chemotherapy backbone
has been created, while the Cisplatin-only PISIC remains
valid for Asian patients, as well as already registered
patients.
- The RECIST criteria have been added in the protocol.
- Additional clarifications, update of contact information
and administrative corrections have been implemented.
Summary of changes from protocol v4.0 to 4.1:
Clarifications included in the protocol about:
- Time Window for tests during the follow up period.
- Treatment administration in case of delay for initiat-
ing the adjuvant treatment.
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